HC Wainwright Issues Positive Estimate for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Rhythm Pharmaceuticals in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their previous estimate of ($0.81). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($2.79) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). The business had revenue of $41.83 million during the quarter, compared to analysts’ expectations of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%.

Other equities analysts have also recently issued reports about the stock. JMP Securities reaffirmed a “market outperform” rating and set a $75.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Canaccord Genuity Group increased their target price on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a report on Thursday, February 27th. TD Cowen lifted their price target on shares of Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Jefferies Financial Group initiated coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price target on the stock. Finally, The Goldman Sachs Group raised their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $69.08.

Rhythm Pharmaceuticals Price Performance

Rhythm Pharmaceuticals stock opened at $52.97 on Thursday. The stock’s 50 day moving average price is $56.79 and its 200 day moving average price is $54.48. The company has a market cap of $3.26 billion, a PE ratio of -12.23 and a beta of 2.30. Rhythm Pharmaceuticals has a 1-year low of $35.17 and a 1-year high of $68.58.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 1,281 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the transaction, the insider now directly owns 2,657 shares in the company, valued at approximately $157,905.51. The trade was a 32.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Christopher Paul German sold 635 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the sale, the chief accounting officer now owns 2,070 shares in the company, valued at $118,445.40. This trade represents a 23.48 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,787 shares of company stock worth $1,901,443. Corporate insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC grew its stake in shares of Rhythm Pharmaceuticals by 79.7% during the 3rd quarter. FMR LLC now owns 50,295 shares of the company’s stock valued at $2,635,000 after buying an additional 22,306 shares during the period. Principal Financial Group Inc. increased its stake in Rhythm Pharmaceuticals by 241.9% during the third quarter. Principal Financial Group Inc. now owns 32,586 shares of the company’s stock worth $1,707,000 after acquiring an additional 23,054 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Rhythm Pharmaceuticals by 307.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,425 shares of the company’s stock worth $756,000 after purchasing an additional 10,882 shares during the period. Creative Planning acquired a new position in shares of Rhythm Pharmaceuticals in the 3rd quarter valued at about $450,000. Finally, Intech Investment Management LLC acquired a new stake in Rhythm Pharmaceuticals during the 3rd quarter worth approximately $649,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.